CAR-T– tag –
-
BioPharma Dive Features Real-World Evidence Analysis of Approved CAR-T Therapies, Unveiling New Insights into Subgroup Efficacy and Long-Term Safety
BioPharma Dive USA Overview BioPharma Dive published an in-depth analysis of post-market real-world data for approved CAR-T cell therapies. The article reveals novel insights into efficacy within specific patient subgroups and the long-t... -
Advanced CAR-T/NK Therapies for Solid Tumors: iPSC-Derived CAR-NK Cells Show Promise in Efficacy and Safety
Oncodaily Global Overview In solid tumor treatment, IL-15 armed GPC3 CAR-T cells demonstrated promising early data, with cytokine release syndrome (CRS) managed by an inducible caspase-9 switch. Notably, iPSC-derived IL-15 incorporated C... -
iPSC-Derived Cell Therapy Pipeline Expands: Hopstem Leads Chinese Market with Neurological and Immunological Disease Applications
BioInformant USA Overview The iPSC-derived cell therapy pipeline is rapidly expanding from disease modeling to clinical applications across cardiovascular, neurological, metabolic, ocular, and oncological diseases. Hopstem Biotechnology ... -
Sonoma Biotherapeutics Automates Autologous CAR-Treg Therapy Manufacturing for Rheumatoid Arthritis with Cellares’ Cell Shuttle Platform
Regen Report USA Overview Sonoma Biotherapeutics partnered with Cellares to automate manufacturing of its Phase 1 autologous CAR-Treg therapy (SBT-77-7101) for treatment-resistant rheumatoid arthritis, using Cellares' Cell Shuttle platfo... -
Eli Lilly Acquires Kelonia and Orna Therapeutics as Investment in In Vivo Cell Therapies Surges, Aiming to Reduce Treatment Burden and Manufacturing Costs
DCAT Value Chain Insights USA Overview In vivo cell therapies, where the patient's body becomes the manufacturing site for cells like CAR T cells, are attracting substantial biopharmaceutical investment due to their potential to reduce t... -
Reinventing CAR T-Cell Access: How Localized Manufacturing in Turkey and China is Driving Down Costs
Bookimed Turkey Overview The prohibitively high cost of CAR T-cell therapy severely limits patient access worldwide, with prices fluctuating significantly based on manufacturing and treatment location. However, localized production, nota... -
Allogeneic CAR-T Manufacturing: Unlocking Rapid, Off-the-Shelf Cancer Therapy
Liv Hospital Turkey Overview Allogeneic CAR-T cell manufacturing is poised to revolutionize cancer treatment by providing 'off-the-shelf' solutions derived from healthy donor cells. This approach dramatically shortens treatment timelines... -
Thermo Fisher Scientific Unveils Semi-Automated, Closed-Loop Workflow for Autologous CAR T Cell Manufacturing: A Leap in Consistency and Safety
Thermo Fisher Scientific USA Overview Thermo Fisher Scientific has introduced a new digitally compatible, semi-automated, closed, and GMP-compliant workflow platform designed to streamline autologous CAR T cell manufacturing. Integrating... -
Methodist Healthcare Expands CAR T-Cell Therapy Trials Beyond Cancer to Autoimmune Diseases like Lupus and MS, Including Pediatric Patients
San Antonio Report USA Overview Methodist Healthcare is expanding CAR T-cell therapy clinical trials beyond oncology, actively researching applications for autoimmune diseases such as Systemic Lupus Erythematosus (SLE) and Multiple Scler... -
Widespread Global Disparities in CAR T-Cell Therapy Access Highlighted; In Vivo CAR-T, Allogeneic Platforms, and Rapid Manufacturing Emerge as Potential Solutions
ASH Clinical News USA Overview Significant global disparities in CAR T-cell therapy access are attributed to high costs, manufacturing complexities, and limited healthcare infrastructure. Novel scientific strategies, including in vivo CA...
